Genexine, Inc. акциялары

Genexine, Inc. is a South Korean clinical-stage biotechnology firm dedicated to advancing and commercializing immunotherapeutics and extended-duration biologics. The company leverages two key proprietary technologies: the hyFc platform, engineered for discovering diverse agonistic protein therapeutics, and an Immune Enhancing Technology, which focuses on therapeutic DNA vaccines. Its extensive pipeline features several drug candidates: GX-H9, currently in Phase II trials for treating growth hormone deficiency in both adults and children; GX-E2, also in Phase II, addressing induced anemia; GX-G3, in Phase II for neutropenia; and GX-G6, undergoing Phase I studies for diabetes. Additionally, GX-188E is in Phase II clinical trials, being evaluated in combination with KEYTRUDA for cervical cancer treatment. Genexine has also forged a co-development alliance with Binex Co. Ltd. to create a COVID-19 vaccine. Founded in 1999 as Genexine Co., Ltd., the company adopted its current name, Genexine, Inc., in March 2013 and is headquartered in Seongnam, South Korea.